Once a relatively obscure class of drugs used for people with diabetes, GLP-1s have now shown an impressive ability to treat obesity, which affects over 100 million Americans. Horizons moderator ...
Biomea Fusion (NASDAQ:BMEA) outlined its focus on diabetes and obesity at the Citizens Life Sciences Conference, highlighting ...
A coalition of Hispanic health and public policy organizations is pushing for New Mexico’s Medicaid program to broaden its coverage of weight loss drugs as treatment for obesity. The policy change, ...
Eli Lilly and Company (NYSE: LLY) is a titan of the pharmaceutical industry, a position bolstered by the monumental success of its GLP-1 diabetes and obesity drug franchise. With products like ...
Pronto survey suggests that whatever be the tactic to capture semaglutide market share, the winners will not simply be those who launch first or have the price lowest or promote the loudest Even as ...
Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.
Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among those on Wegovy than among those on Ozempic.
Kroger said it is now stocking Eli Lilly's injection pen version of the weight-loss drug Zepbound, and will allow self-pay customers to use Lilly's savings card at its retail pharmacies. The ...
Add Yahoo as a preferred source to see more of our stories on Google. Two Nantucket men and a Wareham man are accused of trafficking cocaine after a multi-town investigation following an overdose ...
Diet‑related diseases such as type 2 diabetes, obesity and hypertension, particularly those affecting children, remain ...
Tirzepatide is the active ingredient in Lilly’s popular anti-obesity & diabetes drugs, Mounjaro & Zepbound. Experts say the matter has little relevance for India at present.
A heady combination of influencers, deregulation, GLP-1 success stories and DIY medicine are driving the phenomenal growth in ...